Analysts’ Viewpoint
Surge in prevalence of diverticular diseases, rise in healthcare expenditure, and increase in awareness about the disease are driving North America diverticular treatment market demand. Surge in geriatric population in the region is another factor propelling market progress. Sedentary lifestyle, consumption of diet having low fiber, and intake of high processed foods are expected to bolster North America diverticular treatment market value.
Increase in investment in development of advanced treatment options is projected to offer lucrative opportunities to market players. Post the COVID-19 pandemic, diverticular treatment companies are making data-driven decisions before investing in new products. They are investing significantly in the research and development of advanced diverticular treatment options.
Diverticula are small, bulging pouches that can develop in the lining of the digestive tract, most commonly in the large intestine (colon). When these pouches become inflamed or infected, the condition is known as diverticulitis.
Diverticular treatment refers to the management and medical interventions used to address diverticulitis and its associated symptoms.
Prevalence of diverticular disease has been increasing in North America, posing a significant healthcare challenge. The disease is typically associated with age, and its prevalence tends to increase with advancing age.
According to an article published in the Gastroenterology Journal, more than 50% of Americans older than 60 years of age have diverticulosis, and diverticulitis is highly prevalent.
According to the National Institutes of Health (NIH), the prevalence of diverticular disease reaches as high as 65% by 85 years of age and estimated to be as low as 5% in those 40 years of age or younger in the U.S. Diverticulosis is quite common, especially as people age.
More than 30% of the U.S. adults between the ages of 50 and 59 and more than 70% of those older than 80 years have diverticulosis. Less than 5% of people with diverticulosis develop diverticulitis. In the U.S., about 200,000 people are hospitalized for diverticulitis and about 71,000 people for diverticular bleeding each year.
Rise in life expectancy across the world is increasing the number of elderly individuals. Older people are at higher risk of having diverticular disease, with studies showing that more than half of individuals over the age of 60 have diverticula in their colon.
Changes in dietary habits and lifestyle factors also play a major role in rise in prevalence of diverticular disease. A diet low in fiber and high in processed foods, combined with sedentary lifestyles, could contribute to constipation and increased pressure in the colon, leading to the formation of diverticula.
Obesity has become a major health concern in the region. It is linked to an increased risk of diverticular disease. Excess weight puts additional pressure on the colon, which can contribute to the development of diverticula. These factors are fueling market expansion in the region.
In terms of type, the diverticulitis segment accounted for largest North America diverticular treatment market share in 2022. The trend is expected to continue during the forecast period. Incidence of diverticulitis tends to increase with age, and it is more common in individuals over the age of 50. According to the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), approximately 200,000 cases of acute diverticulitis occur in the U.S. annually.
Based on treatment, the medication segment dominated the diverticular treatment market in North America in 2022. This is ascribed to high demand for diverticular bleeding and diverticulitis treatment antibiotics and anti-inflammatory drugs, which are the most common complications of the diverticular disease.
According to NIDDK, diverticulitis and diverticular bleeding occur in 10% to 25% and up to 15% of people with diverticulosis, respectively. This could require hospitalization and medical interventions. These factors are driving the medication segment.
In terms of route of administration, the oral segment accounted for major market share in 2022. The trend is likely to continue during the forecast period due to ease of administration, high patient compliance, and availability of a range of oral drugs for the treatment of diverticular disease.
Rise in preference for non-invasive treatment options and high demand for antibiotics and anti-inflammatory drugs are expected to bolster the oral segment.
Based on distribution channel, the retail pharmacies segment dominated the market in North America in 2022. This can be ascribed to widespread presence of retail pharmacies. Convenience of retail pharmacies is also a key factor propelling the segment, as patients can easily buy medicine for diverticulitis from retail pharmacies, especially in rural areas where online and hospital pharmacies may be less accessible.
Retail pharmacies also offer personalized and timely services, including counseling, prescription filling, and medication management, which enhance patient satisfaction and loyalty.
According to North America diverticular treatment industry research report, the U.S. accounted for significant share of the regional market in 2022. This can be ascribed to large patient population in the U.S., high prevalence of diverticular disease, availability & adoption of advanced medical treatments on a large scale, and high healthcare spending.
The U.S. also has a well-established pharmaceutical industry, which is influencing the market statistics in the country.
The North America diverticular treatment market report concludes with the company profiles section that includes key information about the major players. Companies focus on strategies such as new product launches, mergers, and partnerships & collaborations to compete in the marketplace. They consider developing new treatments for diverticulitis to strengthen market position.
Major North America diverticular treatment market leaders are Pfizer, Inc., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, Mallinckrodt Pharmaceuticals, Abbott Laboratories, and GSK plc.
Prominent players have been profiled in the report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 986.6 Mn |
|
Forecast (Value) in 2031 |
More than US$ 1.9 Bn |
|
Growth Rate (CAGR) |
7.6% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment as well as country-level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The industry in the region was valued at US$ 986.6 Mn in 2022
It is projected to reach more than US$ 1.9 Bn by 2031
The market in the region is anticipated to expand at a CAGR of 7.6% from 2023 to 2031
Rise in geriatric population is driving the market in the region.
The U.S. is expected to account for largest market share
Pfizer, Inc., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, Mallinckrodt Pharmaceuticals, Abbott Laboratories, and GSK plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: North America Diverticular Treatment Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. North America Diverticular Treatment Market Value Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Disease Prevalence & Incidence Rate
5.2. Pipeline Analysis
5.3. COVID-19 Impact Analysis
6. North America Diverticular Treatment Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Diverticulosis
6.3.2. Diverticulitis
6.3.3. Diverticular Hemorrhage
6.4. Market Attractiveness Analysis, by Type
7. North America Diverticular Treatment Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2017-2031
7.3.1. Medication
7.3.1.1. Pain Reliever
7.3.1.2. Antibiotics
7.3.1.2.1. Amebicides
7.3.1.2.2. Sulfonamides
7.3.1.2.3. Quinolones and Fluoroquinolones
7.3.1.2.4. Lincomycin Derivatives
7.3.1.2.5. Miscellaneous Antibiotics
7.3.1.3. Anticholinergics/Antispasmodics
7.3.2. Nutritional Supplements
7.3.3. Probiotics
7.4. Market Attractiveness Analysis, by Treatment
8. North America Diverticular Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. North America Diverticular Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. North America Diverticular Treatment Market Analysis and Forecast, by Country
10.1. Key Findings
10.2. Market Value Forecast, by Country
10.2.1. U.S.
10.2.2. Canada
10.3. Market Attractiveness Analysis, by Country
11. U.S. Diverticular Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
11.2.1. Diverticulosis
11.2.2. Diverticulitis
11.2.3. Diverticular Hemorrhage
11.3. Market Value Forecast, by Treatment, 2017-2031
11.3.1. Medication
11.3.1.1. Pain Reliever
11.3.1.2. Antibiotics
11.3.1.2.1. Amebicides
11.3.1.2.2. Sulfonamides
11.3.1.2.3. Quinolones and Fluoroquinolones
11.3.1.2.4. Lincomycin Derivatives
11.3.1.2.5. Miscellaneous Antibiotics
11.3.1.3. Anticholinergics/Antispasmodics
11.3.2. Nutritional Supplements
11.3.3. Probiotics
11.4. Market Value Forecast, by Route of Administration, 2017-2031
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Treatment
11.6.3. By Route of Administration
11.6.4. By Distribution Channel
12. Canada Diverticular Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. Diverticulosis
12.2.2. Diverticulitis
12.2.3. Diverticular Hemorrhage
12.3. Market Value Forecast, by Treatment, 2017-2031
12.3.1. Medication
12.3.1.1. Pain Reliever
12.3.1.2. Antibiotics
12.3.1.2.1. Amebicides
12.3.1.2.2. Sulfonamides
12.3.1.2.3. Quinolones and Fluoroquinolones
12.3.1.2.4. Lincomycin Derivatives
12.3.1.2.5. Miscellaneous Antibiotics
12.3.1.3. Anticholinergics/Antispasmodics
12.3.2. Nutritional Supplements
12.3.3. Probiotics
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Treatment
12.6.3. By Route of Administration
12.6.4. By Distribution Channel
13. Competition Landscape
13.1. Market Player - Competition Matrix (by tier and size of companies)
13.2. Market Share Analysis, by Company, 2022
13.3. Company Profiles
13.3.1. Pfizer, Inc.
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Strategic Overview
13.3.2. Novartis AG
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Strategic Overview
13.3.3. Bayer AG
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Strategic Overview
13.3.4. F. Hoffmann-La Roche Ltd.
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Strategic Overview
13.3.5. Teva Pharmaceutical Industries Ltd
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Strategic Overview
13.3.6. Sun Pharmaceutical Industries Ltd.
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Strategic Overview
13.3.7. Johnson & Johnson
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Strategic Overview
13.3.8. Mallinckrodt Pharmaceuticals
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Strategic Overview
13.3.9. Abbott Laboratories
13.3.9.1. Company Overview
13.3.9.2. Product Portfolio
13.3.9.3. SWOT Analysis
13.3.9.4. Strategic Overview
13.3.10. GSK plc
13.3.10.1. Company Overview
13.3.10.2. Product Portfolio
13.3.10.3. SWOT Analysis
13.3.10.4. Strategic Overview
List of Tables
Table 01: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
Table 03: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Medication, 2017-2031
Table 04: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017-2031
Table 05: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 06: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 07: North America Diverticular Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 08: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 09: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
Table 10: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Medication, 2017-2031
Table 11: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017-2031
Table 12: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 13: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 14: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 15: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
Table 16: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Medication, 2017-2031
Table 17: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017-2031
Table 18: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 19: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: North America Diverticular Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: North America Diverticular Treatment Market Value Share, by Type, 2022
Figure 03: North America Diverticular Treatment Market Value Share, by Treatment, 2022
Figure 04: North America Diverticular Treatment Market Value Share, by Route of Administration, 2022
Figure 05: North America Diverticular Treatment Market Value Share, by Distribution Channel, 2022
Figure 06: North America Diverticular Treatment Market Value Share Analysis, by Type, 2022 and 2031
Figure 07: North America Diverticular Treatment Market Attractiveness Analysis, by Type, 2023-2031
Figure 08: North America Diverticular Treatment Market (US$ Mn), by Diverticulosis, 2017-2031
Figure 09: North America Diverticular Treatment Market (US$ Mn), by Diverticulitis, 2017-2031
Figure 10: North America Diverticular Treatment Market (US$ Mn), by Diverticular Hemorrhage, 2017-2031
Figure 11: North America Diverticular Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 12: North America Diverticular Treatment Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 13: North America Diverticular Treatment Market (US$ Mn), by Medication, 2017-2031
Figure 14: North America Diverticular Treatment Market (US$ Mn), by Nutritional Supplements, 2017-2031
Figure 15: North America Diverticular Treatment Market (US$ Mn), by Probiotics, 2017-2031
Figure 16: North America Diverticular Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 17: North America Diverticular Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 18: North America Diverticular Treatment Market (US$ Mn), by Oral, 2017-2031
Figure 19: North America Diverticular Treatment Market (US$ Mn), by Parenteral, 2017-2031
Figure 20: North America Diverticular Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 21: North America Diverticular Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 22: North America Diverticular Treatment Market (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 23: North America Diverticular Treatment Market (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 24: North America Diverticular Treatment Market (US$ Mn), by Online Pharmacies, 2017-2031
Figure 25: North America Diverticular Treatment Market Value Share Analysis, by Country, 2022 and 2031
Figure 26: North America Diverticular Treatment Market Attractiveness Analysis, by Country, 2023-2031
Figure 27: U.S. Diverticular Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 28: U.S. Diverticular Treatment Market Value Share Analysis, by Type, 2022 and 2031
Figure 29: U.S. Diverticular Treatment Market Attractiveness Analysis, by Type, 2023-2031
Figure 30: U.S. Diverticular Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 31: U.S. Diverticular Treatment Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 32: U.S. Diverticular Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 33: U.S. Diverticular Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 34: U.S. Diverticular Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 35: U.S. Diverticular Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 36: Canada Diverticular Treatment Market Value (US$ Mn) Forecast, 2017-2031
Figure 37: Canada Diverticular Treatment Market Value Share Analysis, by Type, 2022 and 2031
Figure 38: Canada Diverticular Treatment Market Attractiveness Analysis, by Type, 2023-2031
Figure 39: Canada Diverticular Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 40: Canada Diverticular Treatment Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 41: Canada Diverticular Treatment Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 42: Canada Diverticular Treatment Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 43: Canada Diverticular Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 44: Canada Diverticular Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 45: North America Diverticular Treatment Market Share, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
North America Diverticular Treatment Market
